selected publications
-
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 37 -
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.
Journal of gynecologic oncology.
2020
Academic Article
GET IT
Times cited: 22 -
Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
Gynecologic oncology.
2019
Academic Article
GET IT
Times cited: 28 -
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate.
EJNMMI research.
2018
Academic Article
GET IT
Times cited: 13 -
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2018
Academic Article
GET IT
Times cited: 7 -
Genetic predisposition to bevacizumab-induced hypertension.
Gynecologic oncology.
2017
Academic Article
GET IT
Times cited: 7 -
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Gynecologic oncology.
2017
Academic Article
GET IT
Times cited: 85 -
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 162 -
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
JAMA oncology.
2016
Academic Article
GET IT
Times cited: 197 -
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Gynecologic oncology.
2015
Academic Article
GET IT
Times cited: 66 -
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2015
Academic Article
GET IT
Times cited: 20 -
Breaking down the evidence for bevacizumab in ovarian cancer.
The oncologist.
2015
Editorial Article
GET IT
Times cited: 3 -
A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.
Investigational new drugs.
2014
Academic Article
GET IT
Times cited: 14 -
Using the neurotransmitter serotonin to target imaging agents to glioblastoma cells.
Investigational new drugs.
2012
Academic Article
GET IT
Times cited: 4 -
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2012
Academic Article
GET IT
Times cited: 172 -
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2012
Academic Article
GET IT
Times cited: 10 -
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.
Cancer.
2012
Academic Article
GET IT
Times cited: 23 -
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Investigational new drugs.
2011
Academic Article
GET IT
Times cited: 10 -
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2011
Academic Article
GET IT
Times cited: 42 -
Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer.
Gynecologic oncology.
2011
Academic Article
GET IT
Times cited: 28 -
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.
Annals of oncology : official journal of the European Society for Medical Oncology.
2010
Academic Article
GET IT
Times cited: 96 -
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010
Academic Article
GET IT
Times cited: 134 -
Consolidation strategies in ovarian cancer: observations for future clinical trials.
Gynecologic oncology.
2010
Academic Article
GET IT
Times cited: 10 -
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
Gynecologic oncology.
2009
Academic Article
GET IT
Times cited: 32 -
A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer.
The oncologist.
2009
Academic Article
GET IT
Times cited: 47 -
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
Gynecologic oncology.
2009
Academic Article
GET IT
Times cited: 165 -
Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy.
Gynecologic oncology.
2008
Academic Article
GET IT
Times cited: 108 -
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008
Academic Article
GET IT
Times cited: 12 -
Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.
Cancer.
2008
Academic Article
GET IT
Times cited: 3 -
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Gynecologic oncology.
2008
Academic Article
GET IT
Times cited: 63 -
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
Nuclear medicine and biology.
2008
Academic Article
GET IT
Times cited: 47 -
A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.
European journal of gynaecological oncology.
2008
Academic Article
GET IT
Times cited: 16 -
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.
Cancer.
2007
Academic Article
GET IT
Times cited: 144 -
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007
Academic Article
GET IT
Times cited: 115 -
Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2007
Academic Article
GET IT
Times cited: 12 -
Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2007
Academic Article
GET IT
Times cited: 42 -
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Gynecologic oncology.
2006
Academic Article
GET IT
Times cited: 50 -
Pancreatic cancer: epidemiology, genetics, and approaches to screening.
Oncology (Williston Park, N.Y.).
2002
Review
GET IT
Times cited: 21 -
Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1.
Journal of virology.
1998
Academic Article
GET IT
Times cited: 123 -
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.
Cell.
1994
Academic Article
GET IT
Times cited: 594 -
Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Cancer chemotherapy and pharmacology.
1990
Academic Article
GET IT
Times cited: 14